The Chinese government accused Mark Reilly, former head of GlaxoSmithKline’s China operations, of directing a bribery and fraud scheme that resulted in higher drug prices and illegal revenue of more than $150 million. The government claimed that Reilly and two other Glaxo executives arranged secret payments to doctors, hospital staff and government officials in order to bolster Glaxo’s drug sales; conducted false transactions in order to transfer illegal gains made in China to overseas companies; and bribed officials to stop investigations of the company. In September 2014, a Chinese court imposed a fine on GlaxoSmithKline and sentenced Reilly and four other company managers to suspended prison terms of up to four years. According to a company press statement, the Changsha Intermediate People’s Court in Hunan Province, China ruled that GSK China Investment Co. Ltd offered money or property to non-government personnel in order to obtain improper commercial gains, and found the company guilty of bribing non-government personnel.